Wanbury Limited
Kedar Raje has extensive experience in the pharmaceutical industry, currently serving as Deputy General Manager at Wanbury Limited since April 2018, where responsibilities encompass AGM for QA/QC, ADL, RA, and PKG. Prior to this role, Kedar Raje gained valuable experience as management staff at Cipa Ltd from 2000 to 2009.
This person is not in any teams
Wanbury Limited
Corporate Profile Towards Better Healthcare… Wanbury Limited, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation. Wanbury’s major thrust area lies in Active Pharmaceutical Ingredient (API) sale in over 70 countries and Pan-India Formulation presence. Active Pharmaceutical Ingredient : Wanbury has a basket of over 13 API products. It is the largest manufacturer of Metformin with over 8500 tons per year. It is the largest exporter of Tramadol to the US market. Wanbury exports to over 50 countries, 65% of which comprises of regulated markets. Has two US-FDA approved multi-product API facilities and one plant under operation for semi-regulated markets. Has been the preferred supplier to some of the top five generic players of the world. Formulations : -Pan-India presence in ethical formulations with a portfolio of close to 70 brands. -Strong presence in gynecology, orthopedics, heamatinics, anti-diabetic, neutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics and general practitioner.